We selected two neuroblastoma cell lines (SK-N-BE2c: MYCN-amplified, SK-N-AS lacking MYCN amplification) in which to evaluate the feasibility of site-specific cytokine transgene integration. The gene discussed is MYCN; the disease is neuroblastoma.